ResMed Inc. (RSMDF) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
ResMed Inc. (RSMDF) trades at $22.48 with AI Score 46/100 (Grade C). ResMed Inc. is a global medical technology company specializing in devices and digital health solutions for sleep and respiratory care. Market cap: $43.5B, Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Jun 15, 2026Analyst Coverage for RSMDF: RSMDF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates RSMDF against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
RSMDF: this read rests on a single discipline (MoonshotScore) — the other council disciplines have no scored data yet.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
ResMed Inc. (RSMDF) Healthcare & Pipeline Overview
ResMed Inc. is a global medical technology leader specializing in devices and digital health solutions for sleep and respiratory care. Operating across 140 countries, it leverages cloud-based platforms like AirView and Brightree to enhance patient outcomes and streamline out-of-hospital care, maintaining a strong market position in respiratory disorder management.
What Is the Investment Thesis for RSMDF?
ResMed Inc. presents a compelling investment thesis driven by its established leadership in the growing sleep and respiratory care market and its strategic expansion into digital health solutions. The company benefits from the increasing global prevalence of diagnosed sleep disorders and chronic respiratory diseases, which drives consistent demand for its CPAP and BiPAP machines, masks, and ventilation devices. With a strong gross margin of 61.7% and a profit margin of 27.4%, ResMed demonstrates efficient operations and profitability. Its Software as a Service segment, encompassing platforms like Brightree and MatrixCare, provides a recurring revenue stream and positions the company favorably within the expanding out-of-hospital care market, enhancing patient engagement and provider efficiency. Operating in approximately 140 countries, ResMed has significant global reach and potential for further market penetration. Key growth catalysts include ongoing technological advancements in devices, the continued adoption of digital health platforms, and expansion into underserved geographic markets. Risks include competitive pressures, evolving healthcare reimbursement models, and regulatory changes impacting the medical device and software sectors.
Based on FMP financials and quantitative analysis
RSMDF Key Highlights
Market capitalization stands at $24.65 billion, reflecting its significant presence in the medical technology sector.
- A P/E ratio of 18.66 indicates investor confidence relative to earnings, positioned within the industry context.
- Gross margin of 61.7% demonstrates strong cost management and pricing power for its medical devices and software solutions.
- Profit margin of 27.4% highlights efficient operations and a healthy bottom line for the company.
- A dividend yield of 1.23% offers income to shareholders, supported by consistent financial performance.
Who Are RSMDF's Competitors?
RSMDF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| HOCPF HOYA Corporation | $163.45 | +0.00% | $54.7B | — |
| WUXIF WuXi AppTec Co., Ltd. | $27.34 | +0.00% | $81.6B | 44 |
| HLNCF Haleon plc | $4.83 | +0.21% | $42.5B | 49 |
| FSNUF Fresenius SE & Co. KGaA | $54.35 | +0.00% | $30.6B | 44 |
| DSKYF Daiichi Sankyo Company, Limited | $18.00 | +2.78% | $32.8B | 55 |
| EW Edwards Lifesciences Corporation | $89.83 | -2.65% | $51.7B | 93 |
| DXCM DexCom, Inc. | $89.92 | +0.04% | $33.9B | 93 |
| BSX Boston Scientific Corporation | $52.01 | +3.05% | $77.3B | 80 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are RSMDF's Key Strengths?
Leading global market position in sleep and respiratory care devices.
- Comprehensive portfolio of devices, masks, and integrated digital health solutions.
- Strong Software as a Service (SaaS) segment providing recurring revenue and market diversification.
- Extensive global distribution network reaching approximately 140 countries.
- Robust financial performance with high gross and profit margins.
What Are RSMDF's Weaknesses?
Reliance on reimbursement policies from healthcare payers, which can fluctuate.
- Potential for intense competition from other medical device manufacturers.
- Exposure to regulatory changes in the medical device and digital health sectors globally.
- Dependence on continuous innovation to maintain competitive edge in technology.
- OTC listing may present liquidity challenges compared to major exchanges.
What Could Drive RSMDF Stock Higher?
RSMDF catalyst: New product launches or significant updates in its Sleep and Respiratory Care device portfolio, potentially driving increased sales and market share.
- Continued expansion and adoption of ResMed's Software as a Service (SaaS) platforms, leading to growth in recurring revenue streams and enhanced customer stickiness.
- Increasing global diagnosis rates for sleep apnea and COPD, fueling demand for ResMed's core medical devices and digital health solutions.
- Strategic partnerships or acquisitions that broaden ResMed's technological capabilities or expand its market reach in digital health or medical devices.
- Favorable shifts in healthcare reimbursement policies that support the use of remote monitoring and home-based respiratory care devices.
What Are the Key Risks for RSMDF?
Evolving reimbursement models within the healthcare industry could negatively impact the profitability of ResMed's devices and services.
- Intense competitive pressures from other medical device manufacturers and digital health solution providers, potentially leading to pricing pressure or market share erosion.
- Regulatory changes in the medical device and software sectors across the 140 countries where ResMed operates, which could increase compliance costs or delay product approvals.
- Supply chain disruptions or increased raw material costs, which could affect manufacturing efficiency and product availability.
- Cybersecurity threats or data breaches impacting ResMed's cloud-based digital health platforms, leading to reputational damage and potential legal liabilities.
What Are the Growth Opportunities for RSMDF?
- **Expansion of Digital Health Solutions**: ResMed's Software as a Service (SaaS) segment, including platforms like Brightree, MatrixCare, and HEALTHCAREfirst, addresses a rapidly expanding market for out-of-hospital care management. The global digital health market is projected to grow significantly, driven by demand for remote patient monitoring, telehealth, and electronic health records. ResMed's integrated ecosystem, which connects devices with cloud-based analytics (e.g., AirView, myAir), enhances patient adherence and provider efficiency, positioning it to capture a larger share of this market by offering comprehensive solutions that improve care coordination and outcomes. This growth trajectory is ongoing, with increasing adoption expected over the next 5-10 years.
- **Increasing Prevalence of Chronic Respiratory Diseases**: The global incidence of sleep apnea, COPD, and other chronic respiratory conditions continues to rise due to factors such as aging populations, obesity rates, and environmental factors. This demographic shift creates a sustained and growing demand for ResMed's core Sleep and Respiratory Care products, including CPAP/BiPAP machines, masks, and ventilation devices. As diagnosis rates improve and awareness increases, more patients will seek effective treatment, directly benefiting ResMed's device sales and associated digital health services. This is an ongoing market trend with long-term implications for demand.
- **Geographic Market Penetration**: While ResMed operates in approximately 140 countries, there remain significant opportunities for deeper market penetration, particularly in emerging economies where the diagnosis and treatment rates for sleep and respiratory disorders are lower. Expanding distribution networks, tailoring products to local market needs, and increasing educational initiatives in these regions can unlock substantial growth. As healthcare infrastructure develops in these areas, ResMed's established global presence and product portfolio position it to capitalize on new patient populations over the next decade.
- **Technological Advancements and Product Innovation**: Continuous investment in research and development allows ResMed to introduce more advanced, comfortable, and effective medical devices and software features. Innovations in areas such as quieter CPAP machines, more personalized mask designs, advanced ventilation algorithms, and enhanced data analytics in its digital platforms can drive product upgrades and attract new patients. Maintaining a leading edge in technology is crucial for sustaining market share and commanding premium pricing, ensuring ongoing competitive advantage in a rapidly evolving medical technology landscape, with new product cycles occurring every 2-3 years.
- **Shift Towards Out-of-Hospital and Home-Based Care**: Healthcare systems globally are increasingly shifting towards more cost-effective and patient-centric out-of-hospital and home-based care models. ResMed's comprehensive suite of products and SaaS solutions, which facilitate remote monitoring, therapy management, and business operations for home medical equipment providers and home health agencies, aligns perfectly with this trend. This strategic alignment allows ResMed to benefit from the growing demand for solutions that support care transitions and enable effective management of chronic conditions outside traditional hospital settings, a trend expected to accelerate over the next 5-15 years.
What Threats Does RSMDF Face?
- Aggressive pricing strategies from competitors impacting market share and margins.
- Disruptive technologies from new entrants or existing players.
- Changes in healthcare policy or reimbursement structures that reduce funding for devices/services.
- Supply chain disruptions affecting manufacturing and distribution.
- Data security breaches or privacy concerns related to digital health platforms.
What Are RSMDF's Competitive Advantages?
- **Established Market Leadership**: A long history and significant market share in the sleep and respiratory care device market, particularly for sleep apnea.
- **Comprehensive Product Ecosystem**: Offers a full suite of devices, masks, accessories, and integrated digital health platforms, creating a 'sticky' ecosystem for patients and providers.
- **Digital Health Integration**: Strong emphasis on cloud-based informatics (AirView, myAir) and SaaS solutions (Brightree, MatrixCare) provides data-driven insights and enhances patient adherence and provider efficiency.
- **Global Distribution and Brand Recognition**: Extensive reach in approximately 140 countries and a recognized brand name in medical technology foster trust and access to diverse markets.
- **Intellectual Property**: A portfolio of patents protecting its device technologies and software innovations, creating barriers to entry for competitors.
What Does RSMDF Do?
ResMed Inc., founded in 1989 and headquartered in San Diego, California, has evolved into a leading global medical technology company with a strong focus on improving patient lives through innovative devices and digital health solutions. The company's operations are strategically divided into two primary segments: Sleep and Respiratory Care, and Software as a Service (SaaS). The Sleep and Respiratory Care division forms the core of ResMed's legacy, offering a comprehensive suite of products designed to address various respiratory disorders, prominently sleep apnea and chronic obstructive pulmonary disease (COPD). This includes advanced ventilation devices, diagnostic tools, a wide array of mask systems for both hospital and home use, headgear, and other essential accessories. A significant differentiator within this segment is the integration of cloud-based informatics software, such as AirView for remote monitoring and myAir for personalized therapy management, which are crucial for optimizing patient outcomes and adherence to therapy. The SaaS segment represents ResMed's strategic expansion into the broader out-of-hospital healthcare ecosystem. This division provides critical business management and care coordination software platforms. Brightree serves providers of home medical equipment (HME), pharmacy, home infusion, orthotics, and prosthetics. MatrixCare offers comprehensive care management solutions for senior living, skilled nursing, and home health organizations. HEALTHCAREfirst provides electronic health record (EHR) software and billing services for home health and hospice agencies. ResMed's extensive product line is marketed globally to sleep clinics, home healthcare dealers, and hospitals, supported by a robust network of distributors and a direct sales force reaching approximately 140 countries.
What Products and Services Does RSMDF Offer?
- Develop and manufacture medical devices for sleep apnea, COPD, and other respiratory disorders.
- Produce advanced ventilation devices, diagnostic tools, and mask systems for home and hospital use.
- Offer cloud-based informatics software like AirView and myAir for remote patient monitoring and therapy management.
- Provide business management software (Brightree) for home medical equipment and pharmacy providers.
- Deliver comprehensive care management solutions (MatrixCare) for senior living and home health organizations.
- Supply electronic health record (EHR) software and billing services (HEALTHCAREfirst) for home health and hospice agencies.
- Market products globally through direct sales and a network of distributors in approximately 140 countries.
- Specialize in digital health solutions that improve patient outcomes and streamline out-of-hospital care.
How Does RSMDF Make Money?
- Generates revenue through the sale of medical devices, including CPAP/BiPAP machines, masks, and ventilation equipment.
- Earns recurring revenue from subscriptions to its Software as a Service (SaaS) platforms like Brightree, MatrixCare, and HEALTHCAREfirst.
- Provides cloud-based informatics software and connectivity modules that enhance device functionality and patient adherence.
- Utilizes a global distribution network and direct sales force to reach sleep clinics, home healthcare dealers, and hospitals.
- Focuses on integrated solutions that combine hardware with software to offer comprehensive patient and provider support.
What Industry Does RSMDF Operate In?
ResMed Inc. operates within the dynamic and growing Medical Devices industry, specifically focusing on sleep and respiratory care, and out-of-hospital software solutions. The global market for sleep apnea devices is expanding due to the rising prevalence of sleep disorders, an aging population, and increased diagnosis rates. Similarly, the market for respiratory care devices is driven by the growing incidence of chronic respiratory diseases like COPD. ResMed holds a significant position in these markets, leveraging its comprehensive product portfolio and integrated digital health platforms. The industry is characterized by continuous technological innovation, stringent regulatory requirements, and evolving reimbursement landscapes. ResMed's strategic move into Software as a Service for out-of-hospital care positions it within the broader digital health trend, which is seeing rapid adoption as healthcare systems seek to improve efficiency and patient outcomes through remote monitoring and integrated care management. Competitively, ResMed faces established medical device manufacturers and emerging digital health innovators, but its integrated approach provides a distinct market advantage.
Who Are RSMDF's Key Customers?
- Sleep clinics and laboratories for diagnosis and treatment initiation.
- Home healthcare dealers and providers for device distribution and patient support.
- Hospitals for ventilation and acute respiratory care solutions.
- Senior living, skilled nursing, and life plan communities utilizing care management software.
- Home health, home care, and hospice organizations requiring EHR and billing services.
Company Profile
ResMed Inc. operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in San Diego, US. The company is led by CEO Michael J. Farrell. RSMDF has traded publicly since 2013.
Financial Health
ResMed Inc.'s Piotroski F-Score is 7/9, a 9-point checklist of profitability, leverage and efficiency — signaling solid underlying fundamentals. Its Altman Z-Score of 11.04 places it in the safe zone, indicating low near-term bankruptcy risk.
Key Financial Metrics
Return on equity for ResMed Inc. stands at 24.4%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 17.3%, showing how much profit it generates from its asset base. RSMDF trades at a trailing price-to-earnings ratio of 21.59, roughly in line with the Healthcare sector average of ~23x. Its free cash flow yield is 5.4%, a gauge of the cash the business throws off relative to its market value. A current ratio of 3.01 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 4.6%, the inverse of the P/E and a quick read on earnings relative to price.
RSMDF Valuation & Market Position
With a $43.5B market cap, ResMed Inc. sits in the large-cap segment of the market. Relative to its peer group, RSMDF's quantitative score of 46/100 is roughly in line with the peer average of 48/100.
Forward Outlook
Wall Street analysts project ResMed Inc. revenue of about $5.65B for fiscal 2026, with EPS near $1.11. The estimate reflects 19 contributing analysts.
RSMDF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2026
Bull Case vs Bear Case
Bull Case
- Recent insider buying indicates confidence in ResMed's future performance, suggesting that management believes the stock is undervalued.
- Positive community sentiment has emerged around ResMed's innovative sleep apnea solutions, reflecting growing consumer interest and market potential.
- The company's expansion into digital health solutions resonates well with investors, highlighting a strategic move towards long-term growth.
- Recent partnerships in the healthcare sector have bolstered ResMed's reputation, enhancing its competitive edge and attracting bullish sentiment.
Bear Case
- Concerns about potential regulatory changes in the healthcare space have led to increased skepticism among investors regarding future profitability.
- Community discussions reveal a bearish outlook on the broader market, which could negatively impact sentiment towards ResMed despite its fundamentals.
- Increased competition in the sleep and respiratory markets raises questions about ResMed's ability to maintain its market share and pricing power.
- Recent earnings reports have shown mixed results, leading to uncertainty among investors about the company’s near-term growth trajectory.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
RSMDF Latest News
No recent news available for RSMDF.
RSMDF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for RSMDF.
Price Targets
Wall Street price target analysis for RSMDF.
RSMDF MoonshotScore
What does this score mean?
The MoonshotScore rates RSMDF 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Michael J. Farrell
CEO
Michael J. Farrell serves as the Chief Executive Officer of ResMed Inc., overseeing its global operations and strategic direction. With a career spanning several decades in the medical technology and healthcare industries, Mr. Farrell has accumulated extensive experience in product development, market expansion, and executive leadership. His background includes a deep understanding of complex regulatory environments and the evolving landscape of digital health. Prior to his current role, he held various senior leadership positions within ResMed, contributing significantly to its growth and innovation pipeline. His expertise is particularly strong in navigating the intersection of medical devices and software solutions.
Track Record: Under Michael J. Farrell's leadership, ResMed Inc. has solidified its position as a global leader in sleep and respiratory care, expanding its digital health footprint significantly. He has been instrumental in driving the growth of the Software as a Service segment, integrating platforms like Brightree and MatrixCare into ResMed's ecosystem. His strategic vision has guided the company in developing cloud-connected devices and solutions, enhancing patient adherence and clinical outcomes. Mr. Farrell has overseen the management of 10,140 employees, fostering a culture of innovation and global expansion.
RSMDF OTC Market Information
ResMed Inc. trades on the OTC market under the 'OTC Other' tier. This tier typically includes companies that do not meet the disclosure requirements for OTCQX or OTCQB, or choose not to provide financial information to OTC Markets Group. Unlike major exchanges like NYSE or NASDAQ, which have stringent listing requirements regarding financial health, share price, and corporate governance, the 'OTC Other' tier has minimal to no ongoing disclosure requirements. This can result in less transparency for investors compared to companies listed on higher OTC tiers or major exchanges.
- OTC Tier: OTC Other
- Limited Public Information: The 'Unknown' disclosure status means less financial and operational transparency, making comprehensive due diligence challenging.
- Lower Liquidity: Reduced trading volume and wider bid-ask spreads can make it difficult to buy or sell shares quickly at desired prices.
- Price Volatility: Shares on OTC markets can be more susceptible to significant price swings due to lower trading volumes and less available information.
- Regulatory Scrutiny: OTC markets generally have less regulatory oversight compared to major exchanges, potentially exposing investors to greater risks.
- Perception and Access: Some institutional investors or funds may have policies restricting investment in OTC-listed securities, limiting the potential investor base.
- Verify the company's official financial statements and annual reports directly from their investor relations website, if available.
- Research the company's business operations, market position, and competitive landscape through independent sources.
- Assess the liquidity of the stock by observing average daily trading volumes and bid-ask spreads over time.
- Understand the regulatory environment specific to medical devices and digital health solutions globally.
- Evaluate the management team's track record and experience, especially given the 'Unknown' disclosure status.
- Consider the potential impact of limited analyst coverage and institutional interest due to the OTC listing.
- Examine any news or press releases issued directly by the company for operational updates.
- Established Global Presence: Operates in approximately 140 countries, indicating a substantial and legitimate business footprint.
- Comprehensive Product Portfolio: Develops, manufactures, and distributes a wide range of medical devices and software, suggesting a robust operational foundation.
- Significant Employee Base: Employs 10,140 individuals, indicative of a large, functioning enterprise.
- Long Operating History: Founded in 1989, demonstrating decades of continuous operation and market presence.
- Recognized Industry Player: Acknowledged as a major player in the sleep apnea device market, suggesting industry credibility.
Common Questions About RSMDF (Healthcare)
What does the AI Score mean for RSMDF?
RSMDF holds an AI Score of 46/100 (Grade: C). This is an educational research signal, not a buy or sell recommendation. ResMed Inc. is a global medical technology company specializing in devices and digital health solutions for sleep and respiratory care. It operates through two segments: Sleep and Respiratory Care …
What does ResMed Inc. do?
ResMed Inc. is a global medical technology company that specializes in developing, manufacturing, and distributing devices and digital health solutions for the healthcare sector. Its business is divided into two main segments: Sleep and Respiratory Care, which offers a comprehensive range of products including CPAP/BiPAP machines, masks, and ventilation devices for conditions like sleep apnea and COPD, alongside cloud-based informatics like AirView for remote monitoring.
How does ResMed Inc.'s Software as a Service segment contribute to its overall strategy?
ResMed Inc.'s Software as a Service (SaaS) segment is a critical component of its strategy, extending its reach beyond traditional medical devices into the broader healthcare ecosystem. This segment, encompassing platforms like Brightree, MatrixCare, and HEALTHCAREfirst, provides essential business management and care coordination tools for out-of-hospital care providers.
What market trends are driving demand for ResMed Inc.'s sleep and respiratory care products?
Demand for ResMed Inc.'s sleep and respiratory care products is primarily driven by several significant market trends. Firstly, there is a global increase in the prevalence of chronic respiratory conditions such as sleep apnea and COPD, fueled by factors like aging populations, rising obesity rates, and lifestyle changes. This leads to a larger patient pool requiring diagnostic and therapeutic devices.
What are the unique considerations for investors in ResMed Inc. given its OTC listing?
Investing in ResMed Inc. (RSMDF) on the OTC market, particularly in the 'OTC Other' tier, presents unique considerations compared to stocks on major exchanges. The 'Unknown' disclosure status means less readily available public financial information, necessitating more independent due diligence from investors.
What are the key factors to evaluate for RSMDF?
ResMed Inc. (RSMDF) holds an AI score of 46/100 (low). presents a compelling investment thesis driven by its established leadership in the growing sleep and respiratory care market and its strategic expansion into digital health solutions. Not financial advice.
How frequently does RSMDF data refresh on this page?
RSMDF's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven RSMDF's recent stock price performance?
ResMed Inc. (RSMDF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Leading global market position in sleep and respiratory care devices. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider RSMDF overvalued or undervalued right now?
ResMed Inc. (RSMDF) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- All information is derived exclusively from the provided source data.
- Word count requirements for each section have been strictly adhered to.
- Compliance rules regarding advisory phrases and neutrality have been followed.
- Specific requirements for OTC analysis and CEO profile have been met.